<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02272556</url>
  </required_header>
  <id_info>
    <org_study_id>1408014461</org_study_id>
    <nct_id>NCT02272556</nct_id>
  </id_info>
  <brief_title>Investigating the Role of the Polyol Pathway in the Central Nervous System</brief_title>
  <official_title>Investigating the Role of Polyol Pathway in the Central Nervous System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients will undergo magnetic resonance spectroscopy (MRS) scanning to noninvasively measure
      intracerebral and plasma metabolite levels at baseline and following 2 and 4 hours of
      hyperglycemia. Subjects will also undergo a lumbar puncture at a separate occasion to assess
      cerebrospinal fluid levels of metabolites.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolite Measurements by MRS</measure>
    <time_frame>4 hours post hyperglycemia</time_frame>
    <description>metabolite levels will be measured by MRS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hunger Ratings</measure>
    <time_frame>4 hours post hyperglycemia</time_frame>
    <description>Hunger will be measured using a visual analog scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satiety Ratings</measure>
    <time_frame>4 hours post hyperglycemia</time_frame>
    <description>Satiety will be measured using a visual analog scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive State</measure>
    <time_frame>4 hours post hyperglycemia</time_frame>
    <description>Participants will be asked to complete basic cognitive testing using the mini-mental status exam and the Montreal cognitive assessment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cerebrospinal fluid cell count</measure>
    <time_frame>2 weeks post MRS testing</time_frame>
    <description>Metabolite levels will be measure in collected spinal fluid</description>
  </other_outcome>
  <other_outcome>
    <measure>protein levels</measure>
    <time_frame>2 weeks post MRS testing</time_frame>
    <description>Metabolite levels will be measure in collected spinal fluid</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>Subjects with Type 2 Diabetes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Type 2 DM subjects with HbA1C &gt; 7.5% treated with metformin, sulfonylurea, insulin or combination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Diabetic Obese</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Age-matched, non-diabetic obese (BMI &gt; 30 kg/m^3) individuals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lean, healthy control subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Age-matched, lean, healthy control subjects (BMI &lt; 25 kkg/m^3)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Brain MRS during hyperglycemic clamp</intervention_name>
    <description>All patients will undergo brain MRS at baseline and following 2 and 4 hours of hyperglycemia using the clamp technique</description>
    <arm_group_label>Subjects with Type 2 Diabetes</arm_group_label>
    <arm_group_label>Non-Diabetic Obese</arm_group_label>
    <arm_group_label>Lean, healthy control subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Analysis of Metabolites in cerebrospinal fluid</intervention_name>
    <description>All patients will have the option to undergo a lumbar puncture for analysis of metabolites in cerebrospinal fluid</description>
    <arm_group_label>Subjects with Type 2 Diabetes</arm_group_label>
    <arm_group_label>Non-Diabetic Obese</arm_group_label>
    <arm_group_label>Lean, healthy control subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 DM with HbA1C treated with metformin, sulfonylurea, insulin, or combination OR
             age-matched, non-diabetic obese (BMI &gt; 30 kg/m^2) OR age-matched lean, healthy control
             subjects (BMI &lt; 25 kg/m^2)

          -  Age 18-55

          -  BMI 18-45 kg/m^2

        Exclusion Criteria:

          -  Creatinine &gt; 1.5 mg/dL

          -  Hgb &lt; 10 mg/dL

          -  ALT &gt; 2.5 x ULN

          -  Untreated thyroid disease

          -  Uncontrolled Hypertension

          -  Known Neurological Disorders

          -  Untreated Psychiatric Disorders

          -  Malignancy

          -  Bleeding Disorders

          -  Smoking

          -  Current or recent steroid use in last 3 months

          -  Illicit drug use

          -  Pregnancy, actively seeking pregnancy, or breastfeeding

          -  Inability to enter MRI/MRS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Sherwin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janice Hwang, MD</last_name>
    <phone>203-785-6222</phone>
    <email>janice.hwang@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janice Hwang, MD</last_name>
      <phone>203-785-6222</phone>
      <email>janice.hwang@yale.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2014</study_first_submitted>
  <study_first_submitted_qc>October 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2014</study_first_posted>
  <last_update_submitted>January 9, 2018</last_update_submitted>
  <last_update_submitted_qc>January 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

